A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...

Pfizer (NYSE:PFE) has entered into a multi-year collaboration with Alloy Therapeutics to develop a new antibody discovery platform. Under the deal, Alloy will receive an upfront payment from Pfizer ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...

Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and ...

Pfizer is back with a 60-second spot for the 2025 game featuring a kid fighting cancer like a boxing champion.